Steve Pearson, ICER president (Jeff Rumans)
February 3, 2022 08:00 AM ESTUpdated 09:07 AM
Pharma
Coronavirus

A rar­i­ty for ICER: Cost watch­dog says Covid-19 ther­a­peu­tics ap­pro­pri­ate­ly priced in the US

Zachary Brennan

Senior Editor

Known as a fer­vent watch­dog over the prices and cost-ef­fec­tive­ness of new phar­ma­ceu­ti­cals, the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) said in a re­port …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Ex­clu­sive: BigHat inks Lil­ly deal for AI-boost­ed an­ti­bod­ies, ex­tends Se­ries B

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times